In the latest trading session, CVS Health (CVS) closed at $44.36, marking a +1.32% move from the previous day.
TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B over 10 years. The multi-year impasse between the DOJ and CVS suggests CVS is confident in its case, and while it is unclear what a final settlement figure may be, it may be a fraction of the $5B 10-year settlement that CVS came to with state and local governments in 2022, the analyst tells investors in a research note.
The U.S. Department of Justice announced a lawsuit against CVS. Transcript: Conway Gittens: There's a rebound on Wall Street Thursday, one-day after stocks suffered their biggest drops since August.
Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.
CVS Health Corp (NYSE:CVS) has been accused by the US Department of Justice of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). A lawsuit filed in Rhode Island claims CVS knowingly knowingly filled prescriptions for opioids that lacked legitimate medical purposes.
The U.S. Department of Justice on Wednesday announced a lawsuit accusing CVS of filling and billing federal health insurance programs for illegal opioid prescriptions.
CVS's stock was headed to its biggest monthly loss in 23 years, as Donald Trump vowed to “knock out” the pharmacy middleman.
CVS Health (CVS) stock price continued its strong downward trend as the company's woes accelerated. Most recently, it has dropped in the last three consecutive weeks, moving to a low of $46.60, its lowest level since March 2020.
Shares of CVS Health Corporation CVS are trading lower on Thursday. This move could break important support.
The pharmacy stock would stand by itself if Walgreens goes private. Wall Street weighs in on the worth of the company's parts.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.